Opinion|Videos|February 2, 2026
Role of APPs in Shared Decision-Making in Alzheimer Disease
Author(s)Ken Cohen, MD, FACP
Panelists discuss how APPs strengthen shared decision-making through education and compassionate communication.
Advertisement
Episodes in this series
Panelists discuss how shared decision-making is vital for empowering patients and caregivers. Advance practice providers (APPs) act as educators who translate complex medical information into understandable terms, supporting informed consent.
Panelists discuss how empathy and communication skills enable APPs to align treatment goals with patient preferences and quality-of-life priorities. Continuous dialogue fosters trust and sustained engagement.
Panelists discuss how APPs ensure ongoing support throughout the disease journey, helping patients revisit decisions as conditions evolve.
Advertisement
Related to this article
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.
Pharmacists are moving beyond order verification into patient education, adverse effect mitigation, and parts of toxicity triage in bispecific care.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
5 Things to Know About HHS's Interim Peptide Compounding Policy
3
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
4
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
5